Excimer Light(308) Therapy for Resistant Alopecia Areata
Study Details
Study Description
Brief Summary
This study aimed to evaluate the efficacy and safety of the 308-nm excimer lamp in resistant AA treated with topical minoxidil .
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
Alopecia areata (AA) is a chronic, nonscarring, T-cell mediated autoimmune disease, presenting with localized or diffuse hair fall in hair-bearing areas. Approximately 1.7% of the population experience an episode of AA during their lifetime. Both sexes are equally affected, and most new cases are recorded below the age of 30 years . Excimer laser using high-dose monochromatic UV radiation can trigger apoptosis and induce immunological suppression through altering cytokine production such as IL-4, IL-10, prostaglandin E2, platelet-activating factor, and cis-urocanic acid. Benefits have only been seen with localized patches of AA, and regrowth of hair occurs only in treated areas .
Study Design
Outcome Measures
Primary Outcome Measures
- alopecia areata with ecimer light [3 months]
evulate patients monthly during treatment with excimer light and minoxidil gel for three months With 20 patients who should completely recovered from alopecia areata.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
● Having multiple patches of AA.
-
Duration of alopecia >1 year
-
No topical or systemic treatment for the last 4 months
-
Agreement to regular visits for treatment and follow-up.
Exclusion Criteria:
-
● A single form of AA.
-
Alopecia for <1 year.
-
Being on other modalities of treatment.
-
Treatment within the last 4 months.
-
Photosensitive disorders.
-
Pregnancy or breastfeeding.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Assiut University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- alopecia areata with excimer